Management of hand-foot syndrome induced by capecitabine
The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
Introduction. Capecitabine (Xeloda®) is a systemic prodrug of 5-fluorouracil (5-FU), which is administered in an oral formulation. Hand-foot syndrome (HFS) has proven to be a chronic dose-limiting toxicity of capecitabine, leading to significant morbidity in patients receiving this agent. The purpose of this review is to define the pathophysiology, risk factors, incidence and management of capecitabine-induced HFS. Methods. Literature for this review article was collected from the following databases: PubMed, CINAHL, and the proceedings of the American Society of Clinical Oncology (ASCO) confined to the years 1995-2006. The following key terms were used in the search: hand-foot syndrome, palmar-plantar erythrodysesthesia, capecitabine, Xeloda®, colorectal cancer, and metastatic breast cancer. Results. HFS associated with capecitabine is a serious dose-limiting toxicity. Incidence of grade 3/4 toxicity is of extreme significance, and introduces the need for dose reductions and/or interruptions in capecitabine therapy. Drug-related therapies studied include topical emollients and creams, systemic and topical corticosteroids, nicotine patch, vitamin E, pyridoxine, and COX-2 inhibitors. However, due to the lack of randomized, controlled trials with these therapies, the current mainstay of treatment for the management of this toxicity is interruption of therapy and, if necessary, dose reduction. Conclusion. Treatment interruption or dose reduction remain the only methods shown to effectively manage HFS, but supportive measures to reduce pain and discomfort and prevent secondary infection are very important. Many other prophylactic and treatment strategies have been investigated, with pyridoxine and COX-2 inhibitors being the most promising in case reports and retrospective studies; therefore, prospective, randomized, controlled trials are needed to prove their efficacy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention Trial
Bresalier, R. S., Sandler, R. S., Quan, H., Bolognese, J. A., Oxenius, B., Horgan, K., Lines, C., Riddell, R., Morton, D., Lanas, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050493 · Cited by 2,519
Cardiovascular Risk Associated with Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention
Solomon, S. D., McMurray, J. J. V., Pfeffer, M. A., Wittes, J., Fowler, R., Finn, P., Anderson, W. F., Zauber, A., Hawk, E., & Bertagnolli, M. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050405 · Cited by 2,052
Miller, K. D., Chap, L. I., Holmes, F. A., Cobleigh, M. A., Marcom, P. K., Fehrenbacher, L., Dickler, M., Overmoyer, B. A., Reimann, J. D., Sing, A. P., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.098 · Cited by 1,306
Capecitabine as Adjuvant Treatment for Stage III Colon Cancer
Twelves, C., Wong, A., Nowacki, M. P., Abt, M., Burris, H., Carrato, A., Cassidy, J., Cervantes, A., Fagerberg, J., Georgoulias, V., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043116 · Cited by 1,248
Hoff, P. M., Ansari, R., Batist, G., Cox, J., Kocha, W., Kuperminc, M., Maroun, J., Walde, D., Weaver, C., Harrison, E., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.8.2282 · Cited by 1,130
Complications of the COX-2 Inhibitors Parecoxib and Valdecoxib after Cardiac Surgery
Nussmeier, N. A., Whelton, A. A., Brown, M. T., Langford, R. M., Hoeft, A., Parlow, J. L., Boyce, S. W., & Verburg, K. M. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050330 · Cited by 1,092
O’Shaughnessy, J., Miles, D., Vukelja, S., Moiseyenko, V., Ayoub, J.-P., Cervantes, G., Fumoleau, P., Jones, S., Lui, W.-Y., Mauriac, L., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.09.002 · Cited by 1,081
Van Cutsem, E., Twelves, C., Cassidy, J., Allman, D., Bajetta, E., Boyer, M., Bugat, R., Findlay, M., Frings, S., Jahn, M., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.21.4097 · Cited by 1,032
Multicenter Phase II Study of Capecitabine in Paclitaxel-Refractory Metastatic Breast Cancer
Blum, J. L., Jones, S. E., Buzdar, A. U., LoRusso, P. M., Kuter, I., Vogel, C., Osterwalder, B., Burger, H.-U., Brown, C. S., & Griffin, T. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.2.485 · Cited by 783
Sch�ller, J., Cassidy, J., Dumont, E., Roos, B., Banken, L., Mori, K., Reigner, B., Utoh, M., Weidekamm, E., & Durston, S. (2000) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800050043 · Cited by 534
(1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.11.3537 · Cited by 495
Cassidy, J., Twelves, C., Van Cutsem, E., Hoff, P., Bajetta, E., Boyer, M., Bugat, R., Burger, U., Garin, A., Graeven, U., et al. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf089 · Cited by 425
Blum, J. L., Dieras, V., Lo Russo, P. M., Horton, J., Rutman, O., Buzdar, A., & Osterwalder, B. (2001) · Cancer · doi:10.1002/1097-0142(20011001)92:7<1759::aid-cncr1691>3.0.co;2-a · Cited by 398
Van Cutsem, E., Findlay, M., Osterwalder, B., Kocha, W., Dalley, D., Pazdur, R., Cassidy, J., Dirix, L., Twelves, C., Allman, D., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.6.1337 · Cited by 318
O’Shaughnessy, J. A., Blum, J., Moiseyenko, V., Jones, S. E., Miles, D., Bell, D., Rosso, R., Mauriac, L., Osterwalder, B., Burger, H.-U., et al. (2001) · Annals of Oncology · doi:10.1023/a:1012281104865 · Cited by 304
Scheithauer, W., McKendrick, J., Begbie, S., Borner, M., Burns, W. I., Burris, H. A., Cassidy, J., Jodrell, D., Koralewski, P., Levine, E. L., et al. (2003) · Annals of Oncology · doi:10.1093/annonc/mdg500 · Cited by 276
Reichardt, P., von Minckwitz, G., Thuss-Patience, P. C., Jonat, W., Kölbl, H., Jänicke, F., Kieback, D. G., Kuhn, W., Schindler, A. E., Mohrmann, S., et al. (2003) · Annals of Oncology · doi:10.1093/annonc/mdg346 · Cited by 237
Bajetta, E., Procopio, G., Celio, L., Gattinoni, L., Della Torre, S., Mariani, L., Catena, L., Ricotta, R., Longarini, R., Zilembo, N., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.167 · Cited by 207
Management of hand-foot syndrome in patients treated with capecitabine (Xeloda®)
Lassere, Y., & Hoff, P. M. (2004) · European Journal of Oncology Nursing · doi:10.1016/j.ejon.2004.06.007 · Cited by 148
Poole, C. J., Gardiner, J., Twelves, C. J., Johnston, P., Harper, P., Cassidy, J., Monkhouse, J., Banken, L., Weidekamm, E., & Reigner, B. G. (2002) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-001-0408-0 · Cited by 134
Feliú, J., Escudero, P., Llosa, F., Naranjo, M. B., Vicent, J. M., Yubero, A., Sanz-Lacalle, J., López‐López, R., López‐Gómez, L., Casado, E., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.035 · Cited by 133
Vail, D. M., Chun, R., Thamm, D. H., Garrett, L., Cooley, A. J., & Obradovich, J. E. (1998) · PubMed · Cited by 122
Capecitabine Monotherapy: Safe and Effective Treatment for Metastatic Breast Cancer
Ershler, W. B. (2006) · The Oncologist · doi:10.1634/theoncologist.11-4-325 · Cited by 102
Effect of celecoxib on capecitabine-induced hand-foot syndrome and antitumor activity.
Lin, E. H., Morris, J. S., & Ayers, G. D. (2002) · PubMed · Cited by 101
Gradishar, W. J., Meza, L., Amin, B., Samid, D., Hill, T. R., Chen, Y.-M., Lower, E. E., & Marcom, P. K. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.12.128 · Cited by 87
Lipton (1995) · Pure Amsterdam UMC · doi:10.1002/1097-0142(19950415)75:8 · Cited by 1
Cited by
Focaccetti, C., Bruno, A., Magnani, E., Bartolini, D., Principi, E., Dallaglio, K., Bucci, E. O., Finzi, G., Sessa, F., Noonan, D. M., et al. (2015) · PLOS ONE · doi:10.1371/journal.pone.0115686 · Cited by 306
Wang, X., Wang, S.-S., Huang, H., Cai, L., Zhao, L., Peng, R.-J., Lin, Y., Tang, J., Zeng, J., Zhang, L.-H., et al. (2021) · JAMA · doi:10.1001/jama.2020.23370 · Cited by 229
Metadata
- Authors
- Gressett, S. M., Stanford, B. L., & Hardwicke, F.
- Venue
- Journal of Oncology Pharmacy Practice
- Publisher
- SAGE Publications
- Published
- 2006-09
- Volume
- 12
- Issue
- 3
- Pages
- 131-141
- ISSN
- 1078-1552 (ISSN-L)
- 1477-092X
- OpenAlex
- W2092325910
- Cited by
- 163
- References
- 26
- FWCI
- 9.39
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.